Pan, Xingyi
Zhou, Jiaojiao
Xiao, Qian
Fujiwara, Kenji
Zhang, Mengwen
Mo, Guanglan
Gong, Wei
Zheng, Lei
Funding for this research was provided by:
National Institutes of Health (R01 CA169702, R01 CA197296)
National Cancer Institute (P50 CA062924)
Sidney Kimmel Comprehensive Cancer Center (P30 CA006973)
Article History
Received: 29 September 2021
Accepted: 8 October 2021
First Online: 2 November 2021
Declarations
:
: Not applicable.
: Not applicable.
: LZ receives grant support from Bristol-Meyer Squibb, Merck, iTeos, Amgen, NovaRock, Inxmed, and Halozyme, and received the royalty for licensing GVAX to Aduro Biotech. LZ is a paid consultant/Advisory Board Member at Biosion, Alphamab, NovaRock, Akrevia/Xilio, Ambrx, Novagenesis, Datarevive, Snow Lake Capitals, and Mingruzhiyao. LZ holds shares at Alphamab and Mingruzhiyao.